Page last updated: 2024-09-02

6-methyl-1,3,8-trichlorodibenzofuran and beta-naphthoflavone

6-methyl-1,3,8-trichlorodibenzofuran has been researched along with beta-naphthoflavone in 1 studies

Compound Research Comparison

Studies
(6-methyl-1,3,8-trichlorodibenzofuran)
Trials
(6-methyl-1,3,8-trichlorodibenzofuran)
Recent Studies (post-2010)
(6-methyl-1,3,8-trichlorodibenzofuran)
Studies
(beta-naphthoflavone)
Trials
(beta-naphthoflavone)
Recent Studies (post-2010) (beta-naphthoflavone)
25031,2380147

Protein Interaction Comparison

ProteinTaxonomy6-methyl-1,3,8-trichlorodibenzofuran (IC50)beta-naphthoflavone (IC50)
Cytochrome P450 1A1Homo sapiens (human)0.054
Cytochrome P450 1A2Homo sapiens (human)0.2767
Tyrosine-protein kinase FynHomo sapiens (human)2.5149
Mitogen-activated protein kinase 3 Homo sapiens (human)5.4667
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)7.185

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Ballarotto, M; Dolciami, D; Fallarino, F; Gargaro, M; López-Cara, LC; Macchiarulo, A1

Reviews

1 review(s) available for 6-methyl-1,3,8-trichlorodibenzofuran and beta-naphthoflavone

ArticleYear
Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs).
    European journal of medicinal chemistry, 2020, Jan-01, Volume: 185

    Topics: Animals; Humans; Immune System Diseases; Immunotherapy; Ligands; Molecular Structure; Receptors, Aryl Hydrocarbon

2020